Table 2.
Diagnostic procedures before the onset of fever or infection in HDC/ASCT recipients
| Population | Intention | Intervention | SoR | QoE | References |
|---|---|---|---|---|---|
| Prior to HDC/ASCT | To detect HBV, HCV, HEV, HIV, and HDV status before release of autologous graft and and ≤ 30 days before HDC/ASCT |
Screening for • HBV (anti-HBc antibodies, HBs antigen, nucleic acid testing) • HCV (anti-HCV, nucleic acid testing) • HEV (nucleic acid testing) • HIV (HIV1/2 antibodies, nucleic acid testing) • Anti-delta if HBsAg positive |
A | III | RiliBÄK Dtsch Arztebl (2019) [40] |
| HBsAg and/or anti-HBc positive | To detect viral reactivation | HBV nucleic acid testing for ≥ 6 months after HDC/ASCT | A | IIu |
Jun Hepatol Int (2017) [42] Kusumoto CID (2015) [44] |
| Unexplained elevated liver function tests | To detect viremia prior to HDC/ASCT | HEV nucleic acid testing | B | IIt |
Von Felden J Hepatol (2019) [100] Furfaro BBMT (2020) [101] |
| CMV-seropositive | To detect CMV viremia and reduce CMV disease and CMV-related mortality | Routine screening for CMV viremia (CMV-PCR) | D | IIu |
Marchesi Hematol Oncol (2018) [102] Kaya Transpl Proc (2017) [103] Massoud JCV (2017) [104] Piukovisc Ann Hematol (2017) [105] |
| HSV-seropositive | To detect HSV viremia and reduce HSV-related mortality | Routine screening for HSV viremia (HSV-PCR) | D | IIu | Inazawa JMV (2017) [76] |
| VZV-seropositive | To detect VZV viremia and reduce VZV-related mortality | Routine screening for VZV viremia (VZV-PCR) | D | III | No reference |
| Any | To reduce mortality and incidence of PTLD | Routine screening for EBV viremia (EBV-PCR) | D | IIu |
Mehra CID (2019) [77] Inazawa JMV (2017) [76] Chiusolo JCI (2010) [106] |
| Any | To reduce the incidence of HHV-6 disease and infection-related mortality | Routine screening for HHV-6 (HHV-6-PCR) | D | IIu |
Balsat J Infect (2019) [75] Inazawa JMV (2017) [76] Piukovics In Vivo (2014) [107] |
| Afebrile, neutropenic | To diagnose blood stream infection with the aim to reduce infection related mortality | Surveillance blood cultures | D | IIu | Ghazal Antimicrob Resist Infect Control (2014) [36] |
| Afebrile, neutropenic | To diagnose invasive aspergillosis | Surveillance serum galactomannan antigen | D | IItu | Duarte CID (2014) [108] |
| Afebrile, neutropenic | To diagnose invasive aspergillosis | Surveillance serum 1,3-β-d-glucan | D | IIt |
Hammerström EJCMID (2015) [109] Cornely JAC (2017) [110] |